CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
REVENUES:
Product Development and Licensing Agreements	$ 1,238	$ 493	$ 2,488	$ 1,551
Contracts and Grants	2,686	1,727	6,799	3,362
Total Revenues	3,924	2,220	9,287	4,913
OPERATING EXPENSES:
Research and Development	21,915	25,009	72,707	78,168
General and Administrative	5,346	6,950	19,109	24,049
In-Process Research and Development Impairment	13,000		13,000
Gain on Fair Value Remeasurement of Contingent Consideration	(4,600)		(200)
Amortization of Acquired Intangible Assets	224	254	672	760
Total Operating Expenses	35,885	32,213	105,288	102,977
Operating Loss	(31,961)	(29,993)	(96,001)	(98,064)
Investment and Other Income, Net	398	395	1,611	1,841
Net Loss Before Income Tax Benefit	(31,563)	(29,598)	(94,390)	(96,223)
Income Tax Benefit	5,200		5,200
Net Loss	$ (26,363)	$ (29,598)	$ (89,190)	$ (96,223)
Basic and Diluted Net Loss Per Common Share (in dollars per share)	$ (0.20)	$ (0.29)	$ (0.71)	$ (0.97)
Shares Used in Calculating Basic and Diluted Net Loss per Share (in shares)	129,640	100,672	125,856	99,398
COMPREHENSIVE LOSS:
Net Loss	$ (26,363)	$ (29,598)	$ (89,190)	$ (96,223)
Other Comprehensive Income:
Unrealized Gain (Loss) on Marketable Securities	11	(113)	47	303
Comprehensive Loss	$ (26,352)	$ (29,711)	$ (89,143)	$ (95,920)